L

Lunit

Biotech & Life Sciences · Seoul, South Korea · Founded 2013 · IPO 2022

Lunit.io is a groundbreaking startup that operates in the healthcare technology sector, specifically focusing on the application of artificial intelligence (AI) in cancer detection and treatment. The company's primary mission is to increase the survival rate of cancer patients by enabling early-stage detection and accurately predicting treatment response. Lunit.io's AI technology serves a broad range of clients, including hospitals, research institutions, and healthcare providers. A notable example is Inje University Paik Hospital, which has introduced Lunit's AI nationwide. The company's business model revolves around providing AI solutions that can be integrated into existing healthcare systems to enhance their diagnostic and treatment capabilities. The company generates revenue by selling its AI solutions to healthcare providers. These solutions help in detecting early-stage cancers, which allows for timely management and increases the chances of survival. Additionally, by accurately predicting treatment response, Lunit's AI helps in increasing the efficacy of immunotherapy, a type of cancer treatment that uses the body's immune system to fight cancer. Lunit.io has been recognized for its innovative approach, ranking first place in the CAMELYON Grand Challenge 2017, a competition focused on AI applications in healthcare. The company also boasts a strong network of global research and business partners, including prominent figures like Kyung Hyun Cho, Interim Deputy Director at the Center for Data Science New York University, and Helmy Eltoukhy, CEO of Guardant Health. Keywords: Artificial Intelligence, Cancer Detection, Cancer Treatment, Healthcare Technology, Early-stage Cancer, Immunotherapy, Inje University Paik Hospital, CAMELYON Grand Challenge, Kyung Hyun Cho, Helmy Eltoukhy.